KRYSTAL BIOTECH INC (KRYS) Stock Fundamental Analysis

NASDAQ:KRYS • US5011471027

287.84 USD
+11.39 (+4.12%)
At close: Feb 17, 2026
287.84 USD
0 (0%)
After Hours: 2/17/2026, 8:27:36 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

6

KRYS gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 521 industry peers in the Biotechnology industry. KRYS is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. KRYS has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • In the past year KRYS was profitable.
  • In the past year KRYS had a positive cash flow from operations.
  • The reported net income has been mixed in the past 5 years: KRYS reported negative net income in multiple years.
  • KRYS had negative operating cash flow in 4 of the past 5 years.
KRYS Yearly Net Income VS EBIT VS OCF VS FCFKRYS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M -150M

1.2 Ratios

  • KRYS has a Return On Assets of 16.04%. This is amongst the best in the industry. KRYS outperforms 95.78% of its industry peers.
  • KRYS's Return On Equity of 17.48% is amongst the best of the industry. KRYS outperforms 95.01% of its industry peers.
  • KRYS's Return On Invested Capital of 12.28% is amongst the best of the industry. KRYS outperforms 95.01% of its industry peers.
Industry RankSector Rank
ROA 16.04%
ROE 17.48%
ROIC 12.28%
ROA(3y)-5.09%
ROA(5y)-7.35%
ROE(3y)-5.33%
ROE(5y)-7.74%
ROIC(3y)N/A
ROIC(5y)N/A
KRYS Yearly ROA, ROE, ROICKRYS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

1.3 Margins

  • KRYS has a better Profit Margin (53.30%) than 98.46% of its industry peers.
  • Looking at the Operating Margin, with a value of 42.40%, KRYS belongs to the top of the industry, outperforming 99.23% of the companies in the same industry.
  • KRYS has a better Gross Margin (94.26%) than 94.63% of its industry peers.
Industry RankSector Rank
OM 42.4%
PM (TTM) 53.3%
GM 94.26%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KRYS Yearly Profit, Operating, Gross MarginsKRYS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

9

2. Health

2.1 Basic Checks

  • KRYS has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • Compared to 1 year ago, KRYS has more shares outstanding
  • KRYS has more shares outstanding than it did 5 years ago.
  • There is no outstanding debt for KRYS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
KRYS Yearly Shares OutstandingKRYS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
KRYS Yearly Total Debt VS Total AssetsKRYS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

  • An Altman-Z score of 48.56 indicates that KRYS is not in any danger for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 48.56, KRYS belongs to the top of the industry, outperforming 95.97% of the companies in the same industry.
  • There is no outstanding debt for KRYS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 48.56
ROIC/WACC1.41
WACC8.68%
KRYS Yearly LT Debt VS Equity VS FCFKRYS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M

2.3 Liquidity

  • KRYS has a Current Ratio of 10.14. This indicates that KRYS is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Current ratio value of 10.14, KRYS belongs to the best of the industry, outperforming 81.77% of the companies in the same industry.
  • KRYS has a Quick Ratio of 9.73. This indicates that KRYS is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Quick ratio value of 9.73, KRYS belongs to the best of the industry, outperforming 81.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 10.14
Quick Ratio 9.73
KRYS Yearly Current Assets VS Current LiabilitesKRYS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • KRYS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 276.84%, which is quite impressive.
  • KRYS shows a strong growth in Revenue. In the last year, the Revenue has grown by 54.51%.
EPS 1Y (TTM)276.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%192.31%
Revenue 1Y (TTM)54.51%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%16.65%

3.2 Future

  • Based on estimates for the next years, KRYS will show a very strong growth in Earnings Per Share. The EPS will grow by 26.78% on average per year.
  • The Revenue is expected to grow by 31.83% on average over the next years. This is a very strong growth
EPS Next Y123.14%
EPS Next 2Y66.89%
EPS Next 3Y50.55%
EPS Next 5Y26.78%
Revenue Next Year33.78%
Revenue Next 2Y37.6%
Revenue Next 3Y36.58%
Revenue Next 5Y31.83%

3.3 Evolution

KRYS Yearly Revenue VS EstimatesKRYS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
KRYS Yearly EPS VS EstimatesKRYS Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5 10 15

More info and screens

Find the best growth stocksShow best growing peers

6

4. Valuation

4.1 Price/Earnings Ratio

  • KRYS is valuated quite expensively with a Price/Earnings ratio of 43.15.
  • Based on the Price/Earnings ratio, KRYS is valued cheaply inside the industry as 91.75% of the companies are valued more expensively.
  • Compared to an average S&P500 Price/Earnings ratio of 27.16, KRYS is valued quite expensively.
  • With a Price/Forward Earnings ratio of 34.56, KRYS can be considered very expensive at the moment.
  • KRYS's Price/Forward Earnings ratio is rather cheap when compared to the industry. KRYS is cheaper than 91.55% of the companies in the same industry.
  • When comparing the Price/Forward Earnings ratio of KRYS to the average of the S&P500 Index (28.10), we can say KRYS is valued slightly more expensively.
Industry RankSector Rank
PE 43.15
Fwd PE 34.56
KRYS Price Earnings VS Forward Price EarningsKRYS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • KRYS's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. KRYS is cheaper than 91.75% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, KRYS is valued cheaper than 92.71% of the companies in the same industry.
Industry RankSector Rank
P/FCF 50.41
EV/EBITDA 42.57
KRYS Per share dataKRYS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • KRYS has a very decent profitability rating, which may justify a higher PE ratio.
  • A more expensive valuation may be justified as KRYS's earnings are expected to grow with 50.55% in the coming years.
PEG (NY)0.35
PEG (5Y)N/A
EPS Next 2Y66.89%
EPS Next 3Y50.55%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • KRYS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

KRYSTAL BIOTECH INC

NASDAQ:KRYS (2/17/2026, 8:27:36 PM)

After market: 287.84 0 (0%)

287.84

+11.39 (+4.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-03
Earnings (Next)02-17
Inst Owners96.44%
Inst Owner Change-1.35%
Ins Owners11.65%
Ins Owner Change-1.34%
Market Cap8.35B
Revenue(TTM)373.16M
Net Income(TTM)198.91M
Analysts86.67
Price Target296.64 (3.06%)
Short Float %10.95%
Short Ratio9.05
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)76.19%
Min EPS beat(2)12.14%
Max EPS beat(2)140.23%
EPS beat(4)3
Avg EPS beat(4)41.54%
Min EPS beat(4)-13.89%
Max EPS beat(4)140.23%
EPS beat(8)4
Avg EPS beat(8)30.53%
EPS beat(12)5
Avg EPS beat(12)2.39%
EPS beat(16)7
Avg EPS beat(16)0.53%
Revenue beat(2)2
Avg Revenue beat(2)2.66%
Min Revenue beat(2)2.42%
Max Revenue beat(2)2.89%
Revenue beat(4)2
Avg Revenue beat(4)-1.53%
Min Revenue beat(4)-10.17%
Max Revenue beat(4)2.89%
Revenue beat(8)4
Avg Revenue beat(8)4.55%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)30.73%
PT rev (3m)34.87%
EPS NQ rev (1m)12.5%
EPS NQ rev (3m)14.6%
EPS NY rev (1m)6.79%
EPS NY rev (3m)30.98%
Revenue NQ rev (1m)-0.08%
Revenue NQ rev (3m)-0.56%
Revenue NY rev (1m)-0.01%
Revenue NY rev (3m)1.34%
Valuation
Industry RankSector Rank
PE 43.15
Fwd PE 34.56
P/S 22.37
P/FCF 50.41
P/OCF 47.37
P/B 7.34
P/tB 7.34
EV/EBITDA 42.57
EPS(TTM)6.67
EY2.32%
EPS(NY)8.33
Fwd EY2.89%
FCF(TTM)5.71
FCFY1.98%
OCF(TTM)6.08
OCFY2.11%
SpS12.87
BVpS39.24
TBVpS39.24
PEG (NY)0.35
PEG (5Y)N/A
Graham Number76.74
Profitability
Industry RankSector Rank
ROA 16.04%
ROE 17.48%
ROCE 13.77%
ROIC 12.28%
ROICexc 33.76%
ROICexgc 33.76%
OM 42.4%
PM (TTM) 53.3%
GM 94.26%
FCFM 44.37%
ROA(3y)-5.09%
ROA(5y)-7.35%
ROE(3y)-5.33%
ROE(5y)-7.74%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0.3
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 213.54%
Cap/Sales 2.84%
Interest Coverage 250
Cash Conversion 107.96%
Profit Quality 83.25%
Current Ratio 10.14
Quick Ratio 9.73
Altman-Z 48.56
F-Score7
WACC8.68%
ROIC/WACC1.41
Cap/Depr(3y)537.2%
Cap/Depr(5y)976.18%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)276.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%192.31%
EPS Next Y123.14%
EPS Next 2Y66.89%
EPS Next 3Y50.55%
EPS Next 5Y26.78%
Revenue 1Y (TTM)54.51%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%16.65%
Revenue Next Year33.78%
Revenue Next 2Y37.6%
Revenue Next 3Y36.58%
Revenue Next 5Y31.83%
EBIT growth 1Y143.62%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year182.48%
EBIT Next 3Y83.71%
EBIT Next 5YN/A
FCF growth 1Y239.07%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y269.59%
OCF growth 3YN/A
OCF growth 5YN/A

KRYSTAL BIOTECH INC / KRYS FAQ

Can you provide the ChartMill fundamental rating for KRYSTAL BIOTECH INC?

ChartMill assigns a fundamental rating of 6 / 10 to KRYS.


What is the valuation status for KRYS stock?

ChartMill assigns a valuation rating of 6 / 10 to KRYSTAL BIOTECH INC (KRYS). This can be considered as Fairly Valued.


What is the profitability of KRYS stock?

KRYSTAL BIOTECH INC (KRYS) has a profitability rating of 6 / 10.


Can you provide the PE and PB ratios for KRYS stock?

The Price/Earnings (PE) ratio for KRYSTAL BIOTECH INC (KRYS) is 43.15 and the Price/Book (PB) ratio is 7.34.


What is the financial health of KRYSTAL BIOTECH INC (KRYS) stock?

The financial health rating of KRYSTAL BIOTECH INC (KRYS) is 9 / 10.